Key Points
- Insider sale: Mauro Stocchi sold 13,649 Stevanato Group shares at an average €21.50, generating €293,453.50. He retains 400,000 shares, with his ownership declining 3.30%.
- Stock and earnings: STVN opened at €20.96, within a €12.89–€27.99 52-week range. The company reported €0.14 quarterly EPS, slightly below the €0.15 consensus, on €302 million in revenue.
- Analyst and institutional sentiment: Analysts hold a consensus “Moderate Buy” rating, while several institutional investors recently initiated or increased positions in the company.
Stevanato Group S.p.A. (NYSE:STVN - Get Free Report) insider Mauro Stocchi sold 13,649 shares of the stock in a transaction on Monday, September 28th. The stock was sold at an average price of €21.50, for a total value of €293,453.50. Following the sale, the insider owned 400,000 shares of the company's stock, valued at approximately €8,600,000. This represents a 3.30% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.
Stevanato Group Stock Performance
Shares of NYSE STVN opened at €20.96 on Thursday. The business's 50-day moving average price is €21.09 and its two-hundred day moving average price is €18.41. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.61 and a quick ratio of 1.08. Stevanato Group S.p.A. has a one year low of €12.89 and a one year high of €27.99. The company has a market capitalization of $6.35 billion, a P/E ratio of 37.42, a price-to-earnings-growth ratio of 1.73 and a beta of 0.75.
Stevanato Group (NYSE:STVN - Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported €0.14 earnings per share for the quarter, missing the consensus estimate of €0.15 by (€0.01). The firm had revenue of €302.00 million during the quarter. Stevanato Group had a return on equity of 10.43% and a net margin of 10.99%. Analysts anticipate that Stevanato Group S.p.A. will post 0.69 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Several equities analysts recently weighed in on STVN shares. UBS Group assumed coverage on shares of Stevanato Group in a research report on Wednesday, September 9th. They set a "neutral" rating and a $23.00 price objective on the stock. Weiss Ratings upgraded shares of Stevanato Group from a "hold (c-)" rating to a "hold (c)" rating in a report on Thursday, August 27th. Finally, TD Cowen raised shares of Stevanato Group to a "strong-buy" rating in a research note on Wednesday, June 17th. Two research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, Stevanato Group currently has a consensus rating of "Moderate Buy".
Get Our Latest Stock Analysis on STVN
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the stock. Wellington Management Group LLP bought a new position in Stevanato Group in the 2nd quarter worth $22,621,000. Ranger Investment Management L.P. bought a new stake in Stevanato Group during the second quarter valued at about $21,438,000. Conestoga Capital Advisors LLC grew its position in shares of Stevanato Group by 7.6% in the first quarter. Conestoga Capital Advisors LLC now owns 8,491,751 shares of the company's stock valued at $116,762,000 after purchasing an additional 602,050 shares during the last quarter. Confluence Investment Management LLC bought a new position in shares of Stevanato Group in the second quarter worth about $6,062,000. Finally, Roubaix Capital LLC lifted its position in shares of Stevanato Group by 96.6% during the 1st quarter. Roubaix Capital LLC now owns 385,316 shares of the company's stock worth $5,298,000 after purchasing an additional 189,343 shares during the last quarter.
About Stevanato Group
(
Get Free Report)
Stevanato Group S.p.A. is an Italy-based provider of drug-containment, drug-delivery and diagnostic solutions for the pharmaceutical, biotechnology and healthcare industries. The company serves customers across the development, production and administration of injectable medicines, with activities spanning pharmaceutical glass packaging, medical devices and manufacturing technologies.
Its product portfolio includes glass vials, cartridges, syringes and other primary containers, as well as ready-to-use packaging solutions such as EZ-fill.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
